Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
Patents for C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
11/2003
11/20/2003US20030216382 Useful for the treatment and/or prophylaxis of diseases associated with dipeptidyl peptidase, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance
11/20/2003US20030216381 Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer
11/20/2003US20030216257 1-aryl-4-alkyl halide-2(1h)-pyridones and their use as herbicides
11/20/2003US20030216248 Catalyst composition and method of polymerization
11/20/2003CA2484968A1 Substituted piperazine as melanocortin receptors ligands
11/19/2003EP1362850A1 Oxime ether compound and agricultural or horticultural bactericide
11/19/2003EP1362846A1 Aminoethanol derivatives
11/19/2003EP1362844A1 Benzylamine analogue
11/19/2003EP1362840A1 Process for the preparation of aromatic and heteroaromatic carboxylic acids via catalytic ozonolysis
11/19/2003EP1362839A2 Liquid crystal composition having a delta-epsilon- of not less than zero and liquid crystal display device
11/19/2003EP1362041A1 Aryl carbamate derivatives, preparation and use thereof
11/19/2003EP1362039A1 Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
11/19/2003EP1362033A1 Pyridine matrix metalloproteinase inhibitors
11/19/2003EP1362028A2 Isophthalic acid derivatives as matrix metalloproteinase inhibitors
11/19/2003EP1362027A2 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical
11/19/2003EP1361873A2 Matrix metalloproteinase inhibitors
11/19/2003EP1361851A1 Primary intermediates for oxidative coloration of hair
11/19/2003EP0973392B1 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
11/19/2003EP0852226B1 Pyrimidine derivatives
11/19/2003EP0809499B1 Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine
11/19/2003CN1457339A Chemokine receptor binding heterocyclic compounds
11/19/2003CN1128139C New piperazine derivatives and its prepn.
11/18/2003US6649657 Prevention of loss and restoration of bone mass by certain prostaglandin agonists
11/18/2003US6649656 Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents
11/18/2003US6649645 Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
11/18/2003US6649639 Inhibit or block the biological activity of the picornaviral 3C protease.
11/18/2003US6649633 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
11/18/2003US6649628 Retinopathy, neuropathy and nephropathy treatment; antidiabetic agents
11/18/2003US6649625 Agent for prophylaxis and treatment of glaucoma
11/18/2003US6649624 Useful as neuropeptide Y receptor antagonists and as agents for therapy of cardiovascular disorders, central nervous system disorders, metabolic diseases
11/18/2003US6649616 For therapy and prophylaxis of cardiovascular disorders caused by ischaemia
11/18/2003US6649613 Diacylhydrazine derivatives
11/18/2003US6649612 Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them
11/18/2003US6649611 Potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
11/18/2003US6649604 Analgesics; antidiabetic agents; antiinflamamtory agents
11/18/2003US6649589 Blocking tumor necrosis factor activity with soluble cytokine receptor, monoclonal antibody or tetracycline derivative
11/18/2003CA2159586C Process for preparing 3-methylpiperidine and 3-methylpyridine by catalytic cyclisation of 2-methyl-1,5-diaminopentane
11/15/2003CA2430171A1 Preparation of aromatic and heteroaromatic carboxylic acids by catalytic ozonolysis
11/13/2003WO2003093283A1 Electroluminescent materials
11/13/2003WO2003093259A1 OPTICALLY ACTIVE β-AMINOKETONES, OPTICALLY ACTIVE 1,3-AMINOALCOHOLS AND METHOD FOR THE PRODUCTION THEREOF
11/13/2003WO2003093254A1 Semicarbazide derivatives for combating thromboembolic diseases
11/13/2003WO2003093250A2 Positive allosteric modulators of the nicotinic acetylcholine receptor
11/13/2003WO2003093242A2 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
11/13/2003WO2003093236A1 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor
11/13/2003WO2003093235A1 Carboxylic acid amides
11/13/2003WO2003093220A1 Process for preparing highly functionalized y-butyrolactams and y-amino acids
11/13/2003WO2003092686A1 Inhibitors of histone deacetylase
11/13/2003WO2003092670A1 Bombesin antagonists
11/13/2003WO2003076417A3 Oxo-azabicyclic compounds
11/13/2003WO2003029200A3 Compounds useful as reversible inhibitors of cysteine proteases
11/13/2003WO2003024448A3 Inhibitors of histone deacetylase
11/13/2003WO2003018059A3 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
11/13/2003WO2002098849A3 Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases
11/13/2003WO2002096879A9 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
11/13/2003WO2002083622A3 Novel aminophenyl ketone derivatives
11/13/2003WO2002077609A3 Identification of compounds for the treatment or prevention of proliferative diseases
11/13/2003WO2002032874A8 Substituted heterocyclic compounds for treating multidrug resistance
11/13/2003WO2002032868A8 2-substituted heterocyclic compounds and their use in treating multidrug resistance
11/13/2003WO2001040188A8 Curcumin analogues for treating cancer
11/13/2003US20030212277 Using 3-sulfonylchloride-4-chloro)pyridine as chemical intermediate
11/13/2003US20030212140 Analgesics; central nervous system disorders
11/13/2003US20030212110 Calcilytic compounds
11/13/2003US20030212097 Osteoporosis, antiarthrtic agents; antitumor agents
11/13/2003US20030212093 Imidazonaphthyridines
11/13/2003US20030212068 Antiinflammatory agents; antiallergens; antiarthritic agents
11/13/2003US20030212067 Bone disorders; rheumatic diseases; wound healing agents
11/13/2003US20030212049 Antiarthritic agents; osteoporosis; sepsis; antiulcer agents; Crohn's disease
11/13/2003CA2485065A1 Semicarbazide derivatives for combating thromboembolic diseases
11/13/2003CA2484582A1 Bombesin antagonists
11/13/2003CA2484065A1 Inhibitors of histone deacetylase
11/13/2003CA2483830A1 Process for preparing highly functionalized y-butyrolactams and y-amino acids
11/13/2003CA2462645A1 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
11/12/2003EP1361214A1 Process for preparing methylthiopyridine
11/12/2003EP1361210A2 Novel immunotherapeutic agents and their use in the reduction of cytokine levels
11/12/2003EP1360173A2 Trisubstituted carbocyclic cyclophilin binding compounds and their use
11/12/2003EP1360170A1 Carboxylic amides, the production and use thereof as medicaments
11/12/2003EP1360168A2 Amphiphilic derivatives for the production of vesicles, micelles and complexants, and precursors thereof
11/12/2003EP1360167A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use
11/12/2003EP1359905A2 Use of mglur5 antagonists for the treatment of pruritic conditions
11/12/2003EP1359900A1 A stable pharmaceutical formulation comprising torsemide modification ii
11/12/2003EP1359892A1 Primary intermediates for oxidative coloration of hair
11/12/2003EP1359890A2 Primary intermediates for oxidative coloration of hair
11/12/2003EP1359887A1 Primary intermediates for oxidative coloration of hair
11/12/2003EP1282614B1 Hydroxamic acid derivatives
11/12/2003EP1214062B1 Use of nicotinic acetylcholine receptor agonists for the preparation of a medicament for the treatment of dry eye disease
11/12/2003EP1208084B1 Tetrahydropyridines as pesticides
11/12/2003EP1206444B1 Compounds that inhibit tryptase activity
11/12/2003EP1115707B1 Benzamide derivatives and ther use as cytokine inhibitors
11/12/2003EP1058549A4 THROMBIN OR FACTOR Xa INHIBITORS
11/12/2003EP0983282B1 Metal complex photosensitizer and photovoltaic cell
11/12/2003EP0760657B1 Novel potent inducers of terminal differentiation and methods of use thereof
11/12/2003CN1455767A Substituted phenylcyclohexane carboxylic acid amides and use thereof
11/12/2003CN1455766A Novel 1,2-diphenylethene derivatives for treatment of immune diseases
11/12/2003CN1127573C Microbiology method for making heteroaromatic carboxylic acid using microbe of alcaligenes
11/12/2003CN1127493C 1-(N-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of phenyl ring
11/12/2003CN1127477C Methods and compositions for lipidization of hydrophilic molecules
11/11/2003US6646149 Derivitives of spermine or its N12-t-butyl carbamate
11/11/2003US6646137 Non-peptide GnRH agents
11/11/2003US6646130 Comprises mixtures of alky esters of 3-(6-methoxy-pyridin-3-yl); for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastasis
11/11/2003US6646129 Cyanoguanidines as cell proliferation inhibitors
1 ... 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 ... 633